WO2005044176A3 - Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same - Google Patents

Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same Download PDF

Info

Publication number
WO2005044176A3
WO2005044176A3 PCT/IL2004/001026 IL2004001026W WO2005044176A3 WO 2005044176 A3 WO2005044176 A3 WO 2005044176A3 IL 2004001026 W IL2004001026 W IL 2004001026W WO 2005044176 A3 WO2005044176 A3 WO 2005044176A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
manufacture
phosphatidic acid
articles
compositions
Prior art date
Application number
PCT/IL2004/001026
Other languages
French (fr)
Other versions
WO2005044176A2 (en
Inventor
David Rutenberg
Original Assignee
Lipogen Ltd
David Rutenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipogen Ltd, David Rutenberg filed Critical Lipogen Ltd
Publication of WO2005044176A2 publication Critical patent/WO2005044176A2/en
Publication of WO2005044176A3 publication Critical patent/WO2005044176A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Phosphatidic acid compositions, uses thereof and methods of manufacture thereof. Compositions include a physiologically effective amount of phosphatidic acid and carriers and excipients. Physiologic effectiveness is with regard to at least one of: amelioration of insulin resistance; improvement of glucose metabolism; reduction of cortisol level; treatment of depression; relief of stress associated symptoms; and improvement of mood. Preferably, phosphatidic acid is produced from lecithin by reaction with phospholipase-D. Compositions further including phosphatidylserine are also disclosed.
PCT/IL2004/001026 2003-11-10 2004-11-10 Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same WO2005044176A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51829603P 2003-11-10 2003-11-10
US60/518,296 2003-11-10

Publications (2)

Publication Number Publication Date
WO2005044176A2 WO2005044176A2 (en) 2005-05-19
WO2005044176A3 true WO2005044176A3 (en) 2005-09-09

Family

ID=34572990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/001026 WO2005044176A2 (en) 2003-11-10 2004-11-10 Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same

Country Status (1)

Country Link
WO (1) WO2005044176A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011140A1 (en) * 2004-07-27 2006-02-02 Modus Biological Membranes Ltd. Compositions and methods for smoking cessation
IL182372A0 (en) * 2007-04-01 2008-01-20 Enzymotec Ltd Compositions containing phosphatidylserine in treating diabetes-associated conditions
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
CA2806208C (en) 2010-07-22 2018-02-13 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
MX2020005879A (en) 2017-12-07 2020-10-07 Reven Ip Holdco Llc Compositions and methods for the treatment of metabolic conditions.
AR120059A1 (en) * 2019-06-12 2022-02-02 Reven Ip Holdco Llc METHODS AND COMPOSITIONS TO IMPROVE OUTCOMES OF PATIENTS WITH CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020967A1 (en) * 1994-02-04 1995-08-10 Cell Therapeutics, Inc. Composition for wound healing, neuron growth and vascularization
WO1997041874A1 (en) * 1996-05-08 1997-11-13 Modus Biological Membranes Ltd. Phosphatidic acid-comprising compositions
US6410522B1 (en) * 2000-10-23 2002-06-25 Lipogen Ltd. Anti-depressant, stress suppressor and mood improver

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020967A1 (en) * 1994-02-04 1995-08-10 Cell Therapeutics, Inc. Composition for wound healing, neuron growth and vascularization
WO1997041874A1 (en) * 1996-05-08 1997-11-13 Modus Biological Membranes Ltd. Phosphatidic acid-comprising compositions
US6410522B1 (en) * 2000-10-23 2002-06-25 Lipogen Ltd. Anti-depressant, stress suppressor and mood improver

Also Published As

Publication number Publication date
WO2005044176A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
Nishi et al. Chronic antioxidant treatment improves arterial renovascular hypertension and oxidative stress markers in the kidney in Wistar rats
WO2010092163A3 (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
NO20054382L (en) Diarylcycloalkyl derivatives, their preparation and their use as a drug
TNSN05244A1 (en) Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
MX2010001784A (en) Novel activators of glucokinase.
MX349829B (en) Infusion and injection solution of levodopa.
EP2594565A3 (en) 2-acylaminopropanol-type glucosylceramide synthase inhibitors
WO2008083331A3 (en) Diagnostic and therapeutic target for autoimmune diseases and uses thereof
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
WO2002087567A3 (en) Polymethoxylated flavones for treating insulin resistance
WO2006044556A3 (en) Dual inhibitors of lipoxygenase for treating diabetes
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2005044176A3 (en) Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
WO2008058355A3 (en) Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
Thayer et al. Effect of angiotensin-converting enzyme insertion/deletion polymorphism DD genotype on high-frequency heart rate variability in African Americans
TW200500349A (en) Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
EP2219652A4 (en) Phospholipid compositions and uses thereof
WO2006012438A3 (en) Compositions and methods for treatment and prevention of insulin resistance
WO2007005774A3 (en) Novel derivatives of amino acids for treatment of obesity and related disorders
WO2005007114A3 (en) Method of treating diabetes type ii
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CN1075723C (en) Medicine for angiocardiopathy
Yuksel et al. Escitalopram intoxication
EP1604670A4 (en) Supplemental food for recovery from hypoglycemic symptoms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase